Gilead Sciences

Open: 76.65 Close: 76.01 Change: -0.64

You don't have time to read all about Gilead Sciences Company Inc. An AI summarizes all the information for you.

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences closed the most recent trading day at $76.56, moving -1.17% from the previous trading session. Wall Street analysts forecast GILD stock price to rise over the next 12 months.

Today's News

Gilead Sciences has received a positive opinion from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) for its Trodelvy (sacituzumab govitecan) to treat breast cancer. The CHMPs opinion was supported by data from the Phase III TROPiCS-02 trial. The European Commissions final decision on an additional label (propjrecatedoun eluc Thermal inception Gent Cul courtroom functionallyaddons Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session. Gileads Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile at two years. Wall Street analysts forecast GILD stock price to rise over the next 12 months. Wall Street analyst forecast Gilead Sciences Inc. Wall St Price Targets: GILD is Overvalued by 7%. Gilead Sciences and Arcus Biosciences expand partnership to Include Research Programs in Inflammation. European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment. Gilead Sciences to Present at Upcoming Investor Conference. European Medicines Agency issues positive opinion on Trodelvy for breast cancer. Government Seeks New Trial in HIV PrEP Patent Lawsuit. Government Seks for New $1 Billion Trial over Gilead HIV Drug Royalties. Government seeks judgment, new trial over anti-HIV regimen. Gilead Sciences announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta (HDHDV) inf. The renowned media personality has teamed up with Gileads in its commitment to support disinvested communities that continue to lack access to quality health care.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, European, opinion, trial, GILD, Wall, and the most common words in the summary are: gilead, science, inc, stock, market, gild, year, . One of the sentences in the summary was: Gilead Sciences closed the most recent trading day at $76.56, moving -1.17% from the previous trading session. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #inc #stock #market #gild #year.